Karyopharm Therapeutics Inc. - Common Stock (KPTI)
3.6600
-0.2000 (-5.18%)
NASDAQ · Last Trade: Apr 5th, 6:21 PM EDT
Detailed Quote
Previous Close
3.860
Open
3.740
Bid
3.600
Ask
4.300
Day's Range
3.512 - 3.890
52 Week Range
3.510 - 21.60
Volume
143,605
Market Cap
417.28M
PE Ratio (TTM)
-3.588
EPS (TTM)
-1.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
159,280
Chart
About Karyopharm Therapeutics Inc. - Common Stock (KPTI)
Karyopharm Therapeutics is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other serious diseases. The company is dedicated to discovering and commercializing innovative oral medications that target and disrupt the abnormal functioning of cellular pathways involved in disease progression. By leveraging its proprietary SINE (Selective Inhibitor of Nuclear Export) platform, Karyopharm aims to improve patient outcomes through the development of therapies that enhance treatment effectiveness while minimizing toxicity. Their research primarily concentrates on hematological cancers and solid tumors, with a commitment to advancing science and addressing significant unmet medical needs in oncology. Read More
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
